Role of NO in the pulmonary artery hyporeactivity to phenylephrine in experimental biliary cirrhosis

European Respiratory Journal

Volumn 9, Issue 3, 1996, Pages 560-564

  Chabot, F ^a,b   Mestiri, H ^a   Sabry, S ^a   Dall'Ava Santucci, J ^a   Lockhart, A ^a   Dinh Xuan, A T ^a  

^a Univ René Descartes ^*  (France)

^b CHU NANCY BRABOIS   (France)

Author keywords

cirrhosis; endothelium; nitric oxide; pulmonary vascular reactivity

Indexed keywords

ACETYLCHOLINE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PHENYLEPHRINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; LIVER CIRRHOSIS; LUNG ARTERY; LUNG CIRCULATION; MALE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; VASCULAR RESISTANCE;

ACETYLCHOLINE; ANIMALS; ARGININE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; LIVER CIRRHOSIS, BILIARY; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; NITROARGININE; NITROPRUSSIDE; PHENYLEPHRINE; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 0029887795     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.96.09030560     Document Type: Article

References (33)

1. Harris P, Heath D. Portal and pulmonary hypertension. In: Harris P, Heath D, eds. The Human Pulmonary Circulation: Its Form and Function in Health and Disease. Edinburgh, Churchill Livingstone, 1986; 444-455.
2. Rodriguez-Roisin R, Agustí AGN, Roca J. The hepatopulmonary syndrome: new name, old complexities. Thorax 1992; 47: 897-902.
3. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet 1991; 337: 776-778.
4. Dinh-Xuan AT, Higenbottam TW, Clelland CA, et al. Impairment of endothelium-dependent pulmonary artery relaxation in chronic obstructive lung disease. N Engl J Med 1991; 324: 1539-1547.
5. Dinh-Xuan AT. Disorders of endothelium-dependent relaxation in pulmonary disease. Circulation 1993; 87 (Suppl. 5): V81-V87.
6. Brashers VL, Peach MJ, Rose CE Jr. Augmentation of hypoxic pulmonary vasoconstriction in the isolated perfused rat lung by in vitro antagonists of endothelium-dependent relaxation. J Clin Invest 1988; 82: 1495-1502.
7. Hasunuma K, Yamaguchi T, Rodman DM, O'Brien RF, McMurtry IF. Effects of inhibitors of EDRF and EDHF on vasoreactivity of perfused rat lungs. Am J Physiol 1991; 260: L97-L104.
8. Liu SF, Crawley DE, Barnes PJ, Evans TW. Endothelium-derived relaxing factor inhibits hypoxic pulmonary vasoconstriction in rats. Am Rev Respir Dis 1991; 143: 32-37.
9. Adnot S, Raffestin B, Eddahibi S, Braquet P, Chabrier PE. Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia. J Clin Invest 1991; 87: 155-162.
10. Barnard JW, Wilson PS, Moore TM, Thompson WJ, Taylor AE. Effect of nitric oxide and cyclo-oxygenase products on vascular resistance in dog and rat lungs. J Appl Physiol 1993; 74: 2940-2948.
11. Hampl V, Archer SL, Nelson DP, Weir EK. Chronic EDRF inhibition and hypoxia: effects on pulmonary circulation and systemic blood pressure. J Appl Physiol 1993; 75: 1748-1757.
12. Isaacson TC, Hampl V, Weir EK, Nelson DP, Archer SL. Increased endothelium-derived NO in hypertensive pulmonary circulation of chronically hypoxic rats. J Appl Physiol 1994; 76: 933-940.
13. Mayoral V, Higenbottam TW, Cremona G, Alexander G, Borland CDR, Jones G. Exhaled nitric oxide is elevated in patients with hepatopulmonary syndrome (Abstract). Am J Respir Crit Care Med 1994; 149: A26.
14. Chang SW, Ohara N. Pulmonary circulatory dysfunction in rats with biliary cirrhosis: an animal model of the hepatopulmonary syndrome. Am Rev Respir Dis 1992; 145: 795-805.
15. Lee SS, Girod C, Braillon A, Hadengue A, Lebrec D. Hemodynamic characterization of chronic bile duct-ligated rats: effect of pentobarbital sodium. Am J Physiol 1986; 251: G176-G180.
16. Zar JH. Biostatistical analysis, 2nd edn. Prentice Hall, Englewood Cliffs, 1984.
17. Daoud FS, Reeves JT, Schaefer JW. Failure of hypoxic pulmonary vasoconstriction in patients with liver cirrhosis. J Clin Invest 1972; 51: 1076-1080.
18. Naeije R, Hallemans R, Mols P, Mélot C. Hypoxic pulmonary vasoconstriction in liver cirrhosis. Chest 1981; 80: 570-574.
19. Rodriguez-Roisin R, Roca J, Agustí AGN, Mastai R, Wagner PD, Bosch J. Gas exchange and pulmonary vascular reactivity in patients with liver cirrhosis. Am Rev Respir Dis 1987; 135: 1085-1092.
20. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43: 109-142.
21. Schini VB, Vanhoutte PM. Inhibitors of calmodulin impair the constitutive but not the inducible nitric oxide synthase activity in the rat aorta. J Pharmacol Exp Ther 1992; 261: 553-559.
22. Zembowicz A, Hatchett RJ, Radziszewski W, Gryglewski RJ. Inhibition of endothelial nitric oxide synthase by ebselen: prevention by thiols suggests the inactivation by ebselen of a critical thiol essential for the catalytic activity of nitric oxide synthase. J Pharmacol Exp Ther 1993; 267: 1112-1118.
23. Yu SM. Thaliporphine selectively inhibits expression of the inducible, but not the constitutive, nitric oxide synthase. Biochem J 1994; 303: 289-294.
24. Wolff DJ, Lubeskie A. Aminoguanidine is an isoform-selective, mechanism-based inactivator of nitric oxide synthesis. Arch Biochem Biophys 1995; 316: 290-301.
25. G-nitro-arginine, a novel, L-arginine reversible inhibitor of endothelium-dependent vasodilatation in vitro. Br J Pharmacol 1990; 99: 408-412.
26. Rolla G, Bucca C, Brussino L. Methylene blue in the hepatopulmonary syndrome (Letter). N Engl J Med 1994; 331: 1098.
27. Pizcueta MP, Pique JM, Bosch J, Whittle BJR, Moncada S. Effects of inhibiting nitric oxide biosynthesis on the systemic and splanchnic circulation of rats with portal hypertension. Br J Pharmacol 1992; 105: 184-190.
28. Lee FY, Albillos A, Colombato LA, Groszmann RJ. The role of nitric oxide in the vascular hyporesponsiveness to methoxamine in portal hypertensive rats. Hepatology 1992; 16: 1043-1048.
29. Sieber CC, Groszmann RJ. In vitro hyporeactivity to methoxamine in portal hypertensive rats: reversal by nitric oxide blockade. Am J Physiol 1992; 262: G996-G1001.
30. Claria J, Jimenez W, Ros J, et al. Pathogenesis of arterial hypotension in cirrhotic rats with ascites: role of endogenous nitric oxide. Hepatology 1992; 15: 343-349.
31. Castro A, Jimenez W, Claria J, et al. Impaired responsiveness to angiotensin II in experimental cirrhosis: role of nitric oxide. Hepatology 1993; 18: 367-372.
32. Taylor SG, Weston AH. Endothelium-derived hyperpolarizing factor: a new endogenous inhibitor from the vascular endothelium. Trends Pharmacol Sci 1988; 9: 272-274.
33. Murad F. Cyclic guanosine monophosphate as a mediator of vasodilatation. J Clin Invest 1986; 78: 1-5.